ATE540693T1 - Impfung und impfstoffe gegen hundeherpesvirus - Google Patents

Impfung und impfstoffe gegen hundeherpesvirus

Info

Publication number
ATE540693T1
ATE540693T1 AT01905858T AT01905858T ATE540693T1 AT E540693 T1 ATE540693 T1 AT E540693T1 AT 01905858 T AT01905858 T AT 01905858T AT 01905858 T AT01905858 T AT 01905858T AT E540693 T1 ATE540693 T1 AT E540693T1
Authority
AT
Austria
Prior art keywords
chv
against canine
vaccination
canine herpesvirus
pregnant
Prior art date
Application number
AT01905858T
Other languages
English (en)
Inventor
Herve Poulet
Original Assignee
Merial Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Sas filed Critical Merial Sas
Application granted granted Critical
Publication of ATE540693T1 publication Critical patent/ATE540693T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01905858T 2000-01-21 2001-01-19 Impfung und impfstoffe gegen hundeherpesvirus ATE540693T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0000797A FR2804026B1 (fr) 2000-01-21 2000-01-21 Vaccination contre l'herpesvirose canine et vaccins
PCT/FR2001/000189 WO2001052887A2 (fr) 2000-01-21 2001-01-19 Vaccination contre l"herpesvirose canine et vaccins

Publications (1)

Publication Number Publication Date
ATE540693T1 true ATE540693T1 (de) 2012-01-15

Family

ID=8846182

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01905858T ATE540693T1 (de) 2000-01-21 2001-01-19 Impfung und impfstoffe gegen hundeherpesvirus

Country Status (13)

Country Link
EP (1) EP1248648B1 (de)
JP (1) JP2003520249A (de)
AT (1) ATE540693T1 (de)
AU (1) AU782657C (de)
BR (2) BR0107771A (de)
CA (1) CA2397861C (de)
FR (1) FR2804026B1 (de)
HU (1) HU228703B1 (de)
MX (1) MXPA02007115A (de)
NZ (1) NZ520242A (de)
PL (1) PL209070B1 (de)
WO (1) WO2001052887A2 (de)
ZA (1) ZA200205830B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003299780A1 (en) 2002-12-19 2004-07-14 Akzo Nobel Patent Department Trivalent vaccine with maternal antibody transfer via the milk
ATE531389T1 (de) * 2005-01-28 2011-11-15 Univ Northwest Lipid- und distickstoffoxidverbindung als hilfsmittel zur erhöhung der impfstoffeffizienz

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
AU532186B2 (en) 1978-07-21 1983-09-22 Merck & Co., Inc. Herpes virus vaccine
JP2746272B2 (ja) * 1987-11-03 1998-05-06 シンテツクス（ユー エス エイ）インコーポレーテツド ワクチンアジュバント
US5753235A (en) * 1996-02-15 1998-05-19 Heska Corporation Recombinant canine herpesviruses
JPH11106351A (ja) * 1997-10-02 1999-04-20 Chemo Sero Therapeut Res Inst オイルアジュバントワクチンおよびその製造方法
US6093564A (en) * 1997-10-03 2000-07-25 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
GB9726555D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine
FR2775601B1 (fr) * 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
FR2776928B1 (fr) * 1998-04-03 2000-06-23 Merial Sas Vaccins adn adjuves

Also Published As

Publication number Publication date
EP1248648A2 (de) 2002-10-16
HUP0203831A3 (en) 2004-07-28
ZA200205830B (en) 2003-09-29
AU3383101A (en) 2001-07-31
CA2397861C (en) 2017-04-04
FR2804026A1 (fr) 2001-07-27
HUP0203831A2 (hu) 2003-03-28
PL356556A1 (en) 2004-06-28
BRPI0107771B1 (pt) 2017-06-13
BR0107771A (pt) 2002-11-12
AU782657C (en) 2006-07-13
AU782657B2 (en) 2005-08-18
FR2804026B1 (fr) 2004-06-11
MXPA02007115A (es) 2003-01-28
WO2001052887A3 (fr) 2002-01-31
WO2001052887A2 (fr) 2001-07-26
EP1248648B1 (de) 2012-01-11
JP2003520249A (ja) 2003-07-02
CA2397861A1 (en) 2001-07-26
PL209070B1 (pl) 2011-07-29
NZ520242A (en) 2004-06-25
HU228703B1 (en) 2013-05-28

Similar Documents

Publication Publication Date Title
NO20015073D0 (no) Vaksiner
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
DE60012042D1 (de) Entepneumovirus und entsprechendes impfstoff
DE60039198D1 (de) Adjuvanszusammensetzungen zur Erhöhung der Immunantwort bezüglich Polynukleotid-basierenden Impfstoffen
WO2007022151A3 (en) Immunization of avians by administration of non-replicating vectored vaccines
YU102103A (sh) Mycoplasma bovis vakcina i postupci redukovanja pneumonije kod životinja
RU2013119946A (ru) Быстрорастворяющаяся лекарственная форма пероральной вакцины, в которой используют крахмал
CY1112575T1 (el) Βελτιωμενα αδρανοποιημενα εμβολια fcv
EP1471936A4 (de) Hiv-vakzine und anwendungsverfahren
DE60136928D1 (de) Verwendung von pflanzen-öl-körper in impfstoffverabreichungsysteme
ATE310008T1 (de) Immunologische adjuvans verbindungen
ATE540693T1 (de) Impfung und impfstoffe gegen hundeherpesvirus
NO20020615L (no) Vaksine
DE602005011041D1 (de) Wachstumshormon-freisetzendes hormon verstärkt die vakzin-induzierte immunantwort
Woodland Vaccine development
MX2022007217A (es) Vacuna epitópica para virus de fiebre porcina africana.
RU2010143584A (ru) Вакцина для защиты от haemophilus parasuis серотипа 4 у поросят
PH12014502085A1 (en) Modified marek`s disease virus, and vaccines made therefrom
AU2003294192A8 (en) Inclusion bodies as antigens for the oral vaccination of animals
UA67249A (en) Strain paramixovirus-3 bovis "m-87" for the preparation of vaccine and diagnostic antigen
Dhama et al. DNA vaccines and prevention of infectious diseases in bovines: A Review
Babiuk Novel approaches for developing vaccines